The emergent success of immune-oncology (IO) drug approvals in multiple tumours has appointed it as the fifth pillar in cancer treatment.
IOs have produced remarkable results as monotherapy in numerous indications, offering a potential to compete with well-established cancer treatments like surgery, radiotherapy, chemotherapy and targeted therapy.
Regardless its discredit and questions like: "What is it about IO therapies if the majority of patients don't have a response to it?" IOs are still delivering the promise to benefit and advance more patients by combining different immunotherapies or by using immunotherapy with the standard of care treatment.
Ultimately the objective already on the horizon with ongoing research is to understand how the immune system works in cancer. For instance, there is still a continuing development and refinement of tumour antigen discovery and novel immunotherapies.
Maxime Bourgognon, Senior Healthcare Analyst at GlobalData, commented: ‘‘The future of IO looks brighter than ever, and IO drugs are now in a position to compete as monotherapies against traditional SOC chemotherapy regimens in the first line of the metastatic setting. In addition, these treatments have shown efficacy in a wide variety of indications offering a less toxic treatment alternative.’’